Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Agile Therapeutics, Inc. Reports Fourth Quarter And Full Year 2016 Financial Results March 8, 2017 Altimmune Expands to New HQ With Plans for New Jobs August 22, 2017 Amag Investors Cheer as Biotech Wins Second Drug Approval This Month February 15, 2018
